Project Grant R43HL176353
Award Date 8/20/25
Completion Date 7/31/26
Dollars Obligated $464K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000.00 to Limax Biosciences Inc. to develop a new hemostatic (bleeding control) hydrogel for advanced surgical applications. The project aims to address unmet needs in bleeding control, which can result in significant postoperative complications and increased healthcare costs. The proposed hydrogel is designed to achieve adhesion energies 100-1,000 times...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...
- This federal Project Grant award of $598,636, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports the development of the EMULAATE platform by Spheric Bio Inc. The EMULAATE technology aims to address the mismatch between standard left atrial appendage occlusion (LAAO) devices and patient anatomy by enabling the assembly of personalized, soft implants directly inside the patient's body through a minimally-invasive procedure. This could...
- The National Heart, Lung, and Blood Institute awarded a $314,362 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nimble Surgical Incorporated for the project "FLEXLOCK - A NOVEL ANCHORING GUIDE CATHETER TO SIMPLIFY TRANSRADIAL COMPLEX PERCUTANEOUS CORONARY INTERVENTIONS." The grant supports the development of an innovative, manually operable FlexLock guide catheter featuring an anchoring tip to provide simultaneous active and passive support for...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $129,021 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to develop injectable liposome nanoparticle crosslinked (LINC) hydrogels for sustained delivery of protein therapeutics to treat myocardial infarction (MI). The research aims to synthesize a library of HA-LINC hydrogels, optimize liposome stabilization, and evaluate the gels' viscoelastic properties,...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...